Researchers have launched a new clinical trial called LUNA-2, aimed at improving treatment options for lung cancer patients. This study will explore a combination of immunotherapy and fecal microbiota transplantation (FMT) to enhance the effectiveness of existing treatments. With a significant investment of $4 million from the Canadian Cancer Society and the Weston Family Foundation, this trial seeks to provide hope for those whose cancer does not respond to standard therapies.

For individuals diagnosed with lung cancer, which is the most common cancer in Canada and the leading cause of cancer-related deaths, this trial could mean better outcomes. Currently, only 27% of lung cancer patients survive more than five years post-diagnosis. By testing this innovative approach, researchers hope to increase survival rates and reduce side effects, potentially transforming the treatment landscape for lung cancer.

The LUNA-2 trial is in the early stages and will involve 160 participants with non-small cell lung cancer. This Phase II study is the largest of its kind in Canada and aims to gather strong evidence on how combining FMT with standard chemotherapy and immunotherapy can improve treatment responses. While the concept of using gut microbiota to enhance cancer treatment is promising, it has not yet been proven in large-scale human trials.

If you or someone you know is facing lung cancer, staying informed about clinical trials like LUNA-2 could be beneficial. Participating in such studies may provide access to cutting-edge treatments that are not yet widely available. Always consult with a healthcare professional to understand the best options based on individual health circumstances.

Source: globenewswire.com